News

John Taylor has joined Ribocure Pharmaceuticals AB as Vice President and Head of Global Business Development. John will lead the

Suzhou Ribo Life Science (Ribo) and Ribocure Pharmaceuticals (Ribocure) presented new data from three projects from its cardiovascular pipeline at

Thanks EASL for a great meeting and also the opportunity to simultaneously show data from our HBV program, both with

We arranged our inauguration ceremony together with both friends and colleagues from academia and industry, as well as many persons

Li-ming Gan, CEO at Ribocure Pharmaceuticals, is for the first time showing our preclinical PoC data at the EASL meeting

Ribocure Pharmaceuticals AB receives Authorisation for a Phase II clinical trial to evaluate efficacy and safety of its novel siRNA

In June we move into the entire fifth floor of the GoCo Clinic building and established a unique “from bench-to-bed”

GoCo House Lunch Launch took place and we were there from Ribocure Pharmaceuticals to meet our future neighbours and potential

World’s first siRNA-based FXI silencing agent enters clinical development – an important step toward a new generation of anti-thrombotic therapies

Ribocure participated in The Innovative Ecosystem at GoCo Arena event and pitched our vision and aims in just 3 minutes.

Visit at GoCo and Gothenburg by one of the founders, Dr Hongyan Zhang, from the parent comany. Impressed and inspired

First tour at the future office. A near 1000 sqm facility with R&D, lab and clinical trail unit will be

Ribocure Pharmaceuticals AB establishes in GoCo Clinic- putting Sweden in the spotlight within oligonucleotide therapeutics GoCo Health Innovation City can